Show simple item record

dc.contributor.authorLopez, Elisabeth
dc.contributor.authorBosch-Camós, Laia
dc.contributor.authorRamirez-Medina, Elizabeth
dc.contributor.authorVuono, Elizabeth
dc.contributor.authorNavas, Maria Jesus
dc.contributor.authorMuñoz, Marta
dc.contributor.authorAccensi, Francesc
dc.contributor.authorZhang, Jinya
dc.contributor.authorAlonso, Uxia
dc.contributor.authorArgilaguet, Jordi
dc.contributor.authorSalas, Maria Luisa
dc.contributor.authorAnachkov, Nikolay
dc.contributor.authorGladue, Douglas P.
dc.contributor.authorBorca, Manuel V.
dc.contributor.authorPina-Pedrero, Sonia
dc.contributor.authorRodriguez, Fernando
dc.contributor.otherProducció Animalca
dc.date.accessioned2021-11-15T13:56:38Z
dc.date.available2021-11-15T13:56:38Z
dc.date.issued2021-08-25
dc.identifier.citationLopez, Elisabeth, Laia Bosch-Camós, Elizabeth Ramirez-Medina, Elizabeth Vuono, Maria Jesus Navas, Marta Muñoz, and Francesc Accensi et al. 2021. "Deletion Mutants Of The Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacy". Viruses 13 (9): 1678. doi:10.3390/v13091678.ca
dc.identifier.issn1999-4915ca
dc.identifier.urihttp://hdl.handle.net/20.500.12327/1404
dc.description.abstractAfrican swine fever (ASF) has become the major threat to the global swine industry. Lack of available commercial vaccines complicates the implementation of global control strategies. So far, only live attenuated ASF viruses (ASFV) have demonstrated solid protection efficacy at the experimental level. The implementation of molecular techniques has allowed the generation of a collection of deletion mutants lacking ASFV-specific virulence factors, some of them with promising potential as vaccine candidates against the pandemic genotype II ASFV strain currently circulating in Africa, Europe, Asia and Oceania. Despite promising results, there is room for improvement, mainly from the biosafety point of view. Aiming to improve the safety of BA71∆CD2, a cross-protective recombinant live attenuated virus (LAV) lacking the ASFV CD2v gene (encoding β-glucuronidase as a reporter gene) available in our laboratory, three new recombinants were generated using BA71∆CD2 as a template: the single mutant BA71∆CD2f, this time containing the fluorescent mCherry reporter gene instead of CD2v, and two double recombinants lacking CD2v and either the lectin gene (EP153R) or the uridine kinase (UK) gene (DP96R). Comparative in vivo experiments using BA71∆CD2f, BA71∆CD2DP96R and BA71∆CD2EP153R recombinant viruses as immunogens, demonstrated that deletion of either DP96R or EP153R from BA71∆CD2f decreases vaccine efficacy and does not improve safety. Our results additionally confirm ASFV challenge as the only available method today to evaluate the protective efficacy of any experimental vaccine. We believe that understanding the fine equilibrium between attenuation and inducing protection in vivo deserves further study and might contribute to more rational vaccine designs in the future.ca
dc.format.extent13ca
dc.language.isoengca
dc.publisherMDPIca
dc.relation.ispartofVirusesca
dc.rightsAttribution 4.0 Internationalca
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleDeletion Mutants of the Attenuated Recombinant ASF Virus, BA71ΔCD2, Show Decreased Vaccine Efficacyca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.relation.projectIDMINECO/Programa Estatal de I+D+I orientada a los retos de la sociedad/AGL2016-78160-C2-1-R/ES/Estrategias de protección frente a la peste porcina africana: de la investigación básica a la aplicada/ca
dc.subject.udc619ca
dc.identifier.doihttps://doi.org/10.3390/v13091678ca
dc.contributor.groupSanitat Animalca


Files in this item

 
 

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/
Share on TwitterShare on LinkedinShare on FacebookShare on TelegramShare on WhatsappPrint